Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

Meiling Gao(Cancer Research UK Cambridge Center), Maurizio Callari(University of Cambridge), Emma Beddowes(Cancer Research UK Cambridge Center), Stephen‐John Sammut(Cancer Research UK Cambridge Center), Marta Grzelak(Cancer Research UK Cambridge Center), Heather Biggs(Cambridge University Hospitals NHS Foundation Trust), Linda Jones(Cancer Research UK), Abdelhamid Boumertit(Cambridge University Hospitals NHS Foundation Trust), Sabine C. Linn(The Netherlands Cancer Institute), Javier Cortés(Instituto Cajal), Mafalda Oliveira(Vall d'Hebron Institute of Oncology), Richard D. Baird(Cancer Research UK), Suet‐Feung Chin(Cancer Research UK Cambridge Center), Carlos Caldas(University of Cambridge)
Genome Medicine
January 4, 2019
Cited by 63Open Access
Full Text

Abstract

Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in oncology. We describe here a fast, flexible and cost-effective method to profile multiple genes simultaneously in low input cell-free DNA (cfDNA): Next Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 amplicons spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free DNA from two HapMap lymphoblastoid cell lines. NG-TAS consistently detected mutations in cfDNA when mutation allele fraction was > 1%. We applied NG-TAS to a clinical cohort of metastatic breast cancer patients, demonstrating its potential in monitoring the disease. The computational pipeline is available at https://github.com/cclab-brca/NGTAS_pipeline .


Related Papers

No related papers found

Powered by citation graph analysis